Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - linaclotide, quantity: 0.145 mg - capsule, hard - excipient ingredients: microcrystalline cellulose; calcium chloride dihydrate; leucine; hypromellose; titanium dioxide; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; shellac; sulfuric acid - constella is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (ibs-c) and ? chronic idiopathic constipation (cic) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - linaclotide, quantity: 0.072 mg - capsule, hard - excipient ingredients: histidine; polyvinyl alcohol; calcium chloride dihydrate; purified talc; microcrystalline cellulose; titanium dioxide; potable water; gelatin; sodium lauryl sulfate; propylene glycol; butan-1-ol; ethanol; iron oxide yellow; strong ammonia solution; iron oxide black; methanol; shellac; sulfuric acid - constella is indicated in adults for the treatment of: ? irritable bowel syndrome with constipation (ibs-c) and ? chronic idiopathic constipation (cic) when dietary fibre, laxatives and stool softeners have not been sufficient and with adequate constipation minimisation dietary support.

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nuvista pharma ltd - linaclotide - capsule - 72 mcg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

allergan inc, united states - linaclotide - capsule - 290 µg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

allergan inc, united states - linaclotide - capsule - 145 µg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

nuvista pharma ltd - linaclotide - capsule - 290 mcg

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

astellas pharama inc. - linaclotide - pale yellow tablets, diameter: approx. 6.6 mm, thickness: approx. 3.1 mm

New Zealand - English - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - linaclotide 0.145mg;  ;   - capsule - 145 mcg - active: linaclotide 0.145mg     excipient: calcium chloride dihydrate capsugel linaclotide fl 145 (18213) hydrochloric acid hypromellose leucine microcrystalline cellulose opacode gray s-1-175002 - constella is indicated in adults for the treatment of: · irritable bowel syndrome with constipation (ibs-c) and

New Zealand - English - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - linaclotide 0.29mg;  ;   - capsule - 290 mcg - active: linaclotide 0.29mg     excipient: calcium chloride dihydrate capsugel linaclotide gelatine s 2 (18212) hydrochloric acid hypromellose leucine microcrystalline cellulose opacode gray s-1-175002 - constella is indicated in adults for the treatment of: · irritable bowel syndrome with constipation (ibs-c) and

New Zealand - English - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - linaclotide 0.072mg;  ;   - capsule - 72 mcg - active: linaclotide 0.072mg     excipient: calcium chloride dihydrate capsugel linzess 72mcg (45468) histidine hydrochloric acid microcrystalline cellulose opacode gray s-1-175002 polyvinyl alcohol purified talc - constella is indicated in adults for the treatment of: · irritable bowel syndrome with constipation (ibs-c) and